Curated News
By: NewsRamp Editorial Staff
November 07, 2026
Intensive Blood Pressure Control Cuts Recurrent Stroke Risk by 21%
TLDR
- Stroke survivors can gain a 21% lower risk of major cardiovascular events by targeting systolic blood pressure below 120 mm Hg.
- The OPTIMAL-Stroke trial randomized 4,368 Brazilian stroke survivors to intensive (under 120 mm Hg) or standard (under 140 mm Hg) systolic blood pressure targets and tracked cardiovascular outcomes over four years.
- Intensive blood pressure control after stroke could prevent recurrent strokes and save lives, making tomorrow better for survivors and their families.
- Lowering systolic blood pressure below 120 mm Hg reduced recurrent strokes from 6.4% to 4.7% in stroke survivors, but kidney monitoring is advised.
Impact - Why it Matters
This news matters because nearly 185,000 recurrent strokes occur annually in the U.S., and high blood pressure is the leading modifiable risk factor. For the millions of stroke survivors worldwide, these findings suggest that more aggressive blood pressure lowering—when done safely under medical supervision—could substantially reduce the risk of another stroke, heart attack, or cardiovascular death. The results may prompt healthcare providers to reconsider blood pressure targets for this high-risk group, potentially reshaping clinical guidelines and improving long-term outcomes. Patients should discuss their individual blood pressure goals with their healthcare team to balance benefits and risks.
Summary
New late-breaking research presented at the American Heart Association’s Scientific Sessions 2026 in Chicago suggests that intensive blood pressure control can significantly reduce the risk of recurrent cardiovascular events in stroke survivors. The OPTIMAL-Stroke Trial, conducted at 30 health centers in Brazil between 2019 and 2022, enrolled 4,368 adults with a history of ischemic stroke or transient ischemic attack (TIA). Participants were randomly assigned to either intensive treatment targeting systolic blood pressure below 120 mm Hg or standard treatment targeting below 140 mm Hg. Over an average follow-up of 3.9 years, the intensive group experienced a 21% lower risk of major cardiovascular events, including cardiovascular death, heart attack, stroke, and hospitalization for unstable angina or heart failure. Cardiovascular events occurred in 10.9% of the intensive group versus 13.5% of the standard group, and recurrent strokes were also reduced (4.7% vs. 6.4%).
“Controlling blood pressure after a stroke is especially important because it can help prevent another stroke, prevent other cardiovascular complications and protect patients’ lives,” said Otavio Berwanger, M.D., Ph.D., chair of the OPTIMAL study Steering Committee. The study’s principal investigator, Gisele Sampaio, M.D., Ph.D., emphasized that achieving lower blood pressure safely requires medical supervision and monitoring of kidney function. Serious adverse events were similar between groups, though kidney-related events were more common with intensive treatment. The findings align with the American Heart Association/American College of Cardiology 2025 Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults, which encourages blood pressure targets below 120 mm Hg for high-risk individuals. The trial was simultaneously published in the New England Journal of Medicine.
High blood pressure is the single most important modifiable risk factor for stroke, and these results underscore the potential of personalized, intensive treatment to prevent recurrent events. However, the researchers note limitations: not all participants achieved the target, and the findings may not be generalizable outside Brazil due to differences in healthcare access and environmental factors. Further research is needed to confirm long-term benefits and safety across diverse populations.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Intensive Blood Pressure Control Cuts Recurrent Stroke Risk by 21%
